Cypress Capital Management (Wyoming)’s Iterum Therapeutics ITRM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3 | Hold |
66
| – | – | ﹤0.01% | 213 |
|
|
2026
Q1 | $2 | Hold |
66
| – | – | ﹤0.01% | 205 |
|
|
2025
Q4 | $22 | Hold |
66
| – | – | ﹤0.01% | 205 |
|
|
2025
Q3 | $44 | Buy |
+66
| New | +$52 | ﹤0.01% | 175 |
|
|
2025
Q1 | – | Sell |
-66
| Closed | -$117 | – | 169 |
|
|
2024
Q4 | $117 | Hold |
66
| – | – | ﹤0.01% | 145 |
|
|
2024
Q3 | $72 | Buy |
+66
| New | +$79 | ﹤0.01% | 161 |
|
|
2024
Q1 | – | Sell |
-66
| Closed | -$130 | – | 178 |
|
|
2023
Q4 | $130 | Hold |
66
| – | – | ﹤0.01% | 166 |
|
|
2023
Q3 | $53 | Hold |
66
| – | – | ﹤0.01% | 175 |
|
|
2023
Q2 | $71 | Hold |
66
| – | – | ﹤0.01% | 172 |
|
|
2023
Q1 | $66 | Hold |
66
| – | – | ﹤0.01% | 163 |
|
|
2022
Q4 | $55 | Hold |
66
| – | – | ﹤0.01% | 161 |
|
|
2022
Q3 | $0 | Sell |
66
-1
| -1% | -$3 | ﹤0.01% | 166 |
|
|
2022
Q2 | $0 | Hold |
67
| – | – | ﹤0.01% | 180 |
|
|
2022
Q1 | $0 | Hold |
67
| – | – | ﹤0.01% | 228 |
|
|
2021
Q4 | $0 | Hold |
67
| – | – | ﹤0.01% | 290 |
|
|
2021
Q3 | $1K | Hold |
67
| – | – | ﹤0.01% | 234 |
|
|
2021
Q2 | $2K | Hold |
67
| – | – | ﹤0.01% | 283 |
|
|
2021
Q1 | $1K | Hold |
67
| – | – | ﹤0.01% | 278 |
|
|
2020
Q4 | $1K | Hold |
67
| – | – | ﹤0.01% | 223 |
|
|
2020
Q3 | $1K | Hold |
67
| – | – | ﹤0.01% | 202 |
|
|
2020
Q2 | $1K | Hold |
67
| – | – | ﹤0.01% | 193 |
|
|
2020
Q1 | $3K | Hold |
67
| – | – | ﹤0.01% | 163 |
|
|
2019
Q4 | $5K | Hold |
67
| – | – | ﹤0.01% | 159 |
|
|
2019
Q3 | $6K | Hold |
67
| – | – | 0.01% | 160 |
|
|
2019
Q2 | $7K | Hold |
67
| – | – | 0.01% | 204 |
|
|
2019
Q1 | $8K | Hold |
67
| – | – | 0.01% | 198 |
|
|
2018
Q4 | $5K | Hold |
67
| – | – | 0.01% | 252 |
|
|
2018
Q3 | $7K | Hold |
67
| – | – | 0.01% | 290 |
|
|
2018
Q2 | $11K | Buy |
+67
| New | +$12.1K | 0.01% | 257 |
|
Other funds holding ITRM
Cypress Capital Management (Wyoming)'s ITRM Position: Q2 2026 in Review
Cypress Capital Management (Wyoming) held its Iterum Therapeutics (ITRM) position steady in Q2 2026 at 66 shares worth $3. The position accounts for ﹤0.01% of the portfolio, ranked #213.
Cypress Capital Management (Wyoming) first reported a position in ITRM in Q2 2018 and has held it in 29 quarters since. The position peaked at $11K in Q2 2018. 2 funds tracked by Wall St. Rank hold ITRM as of Q2 2026.
- Cypress Capital Management (Wyoming) held 66 shares of Iterum Therapeutics worth $3 as of Q2 2026.
- Cypress Capital Management (Wyoming) left its Iterum Therapeutics share count unchanged in Q2 2026.
- Iterum Therapeutics made up ﹤0.01% of Cypress Capital Management (Wyoming)'s portfolio in Q2 2026, its #213 holding.
- Cypress Capital Management (Wyoming) first reported a position in Iterum Therapeutics in Q2 2018 and has held it in 29 quarters since.
- Cypress Capital Management (Wyoming)'s Iterum Therapeutics position peaked at $11K in Q2 2018.
- 2 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2026.
Based on Cypress Capital Management (Wyoming)'s 13F filing for Q2 2026, filed 6 Aug 2026.